# US 2019/0314199 A1 · Implants with controlled drug delivery features and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314199 A1
- Document ID: US20190314199A1
- Status: Published application
- Kind: A1
- Application number: 16/277,858
- Filed: 2019-02-15
- Published: 2019-10-17
- Earliest claimed: 2009-05-18
- Assignees: Dose Medical Corporation
- Applicants: Dose Medical Corporation
- Inventors: David S. Haffner; Thomas W. Burns; Harold A. Heitzmann; Kenneth M. Curry
- Web page: https://patentgrep.com/patent/US20190314199A1

## CPC

- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61F 9/00781: {Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment (drainage implants in general A61M27/002)}
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

A drug delivery ocular implant comprising:
an outer shell having a first end and a second closed end, the first end being at least partially open, the outer shell being shaped to define an interior cavity;
at least a first drug positioned within the interior cavity;
an elastic membrane permeable or semi-permeable to the at least a first drug, the membrane positioned at the first end of the outer shell and mechanically affixed to the outer shell to form a gasket to close the first end; and
a retention protrusion on the second closed end of the outer shell, wherein the retention protrusion is configured to anchor the ocular implant at a target tissue site in an eye.

### Claim 16 (depends on 15)

The implant of claim 15, wherein the gasket limits the fluid communication between interior and exterior portions to that occurring through the elastic membrane.

### Claim 17 (depends on 15)

The implant of claim 15, wherein the outer shell comprises one or more surface irregularities which extend from the surface of the outer shell to inhibit migration of the implant from an implanted position.

### Claim 18 (depends on 17)

The implant of claim 17, wherein the surface irregularity is anchored in position by friction fit to prevent growth of tissue.

### Claim 19 (depends on 17)

The implant of claim 17, wherein the one or more surface irregularities comprise one or more of ridge, groove, relief, annular groove, ribbing, or projections.

### Claim 20 (depends on 15)

The implant of claim 15, wherein the implant comprises one or more annular ribs on an exterior surface of the implant.

### Claim 21 (depends on 20)

The implant of claim 20, wherein the plurality of annular ribs are spaced longitudinally along the implant between the proximal end and the distal end.

### Claim 22 (depends on 15)

The implant of claim 15, wherein the retention protrusion is barb-like or spike-like.

### Claim 23 (depends on 15)

The implant of claim 15, wherein the first drug is selected from a prostaglandin, a prostaglandin analog, and a prostaglandin inhibitor.

### Claim 24 (depends on 23)

The implant of claim 23, wherein the first drug is travoprost.

### Claim 25

A drug delivery ocular implant comprising:
an outer shell shaped to define an interior space, the outer shell having a sidewall, one closed distal end, and one proximal end, the proximal end being at least partially open;
at least a first drug contained within the interior space;
a membrane mechanically affixed to and sealing the proximal end, the membrane controlling flow of the drug out of the implant; and
an anchor on the closed distal end.

### Claim 26 (depends on 25)

The implant of claim 25, wherein the outer shell comprises one or more surface irregularities which extend from the surface of the outer shell to inhibit migration of the implant from an implanted position.

### Claim 27 (depends on 26)

The implant of claim 26, wherein the one or more surface irregularities comprise one or more of ridge, groove, relief, hole, annular groove, barbs, ribbing, or projection.

### Claim 28 (depends on 25)

The implant of claim 25, wherein the implant comprises one or more annular ribs on an exterior surface of the implant.

### Claim 29 (depends on 28)

The implant of claim 28, wherein the plurality of annular ribs are spaced longitudinally along the implant between the proximal end and the distal end.

### Claim 30 (depends on 25)

The implant of claim 25, wherein the retention protrusion is barb-like or spike-like.

### Claim 31 (depends on 25)

The implant of claim 25, wherein the first drug is selected from a prostaglandin, a prostaglandin analog, and a prostaglandin inhibitor.

### Claim 32 (depends on 31)

The implant of claim 31, wherein the first drug is travoprost.

### Claim 33 (depends on 25)

The implant of claim 25, wherein the membrane is permeable or semi-permeable to the first drug.
